These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25368259

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.
    Dean EJ, Ward T, Pinilla C, Houghten R, Welsh K, Makin G, Ranson M, Dive C.
    Br J Cancer; 2010 Jan 05; 102(1):97-103. PubMed ID: 19904270
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
    Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP.
    Radiother Oncol; 2011 Oct 05; 101(1):183-9. PubMed ID: 21722984
    [Abstract] [Full Text] [Related]

  • 28. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
    Abaza MS, Bahman AM, Al-Attiyah RJ.
    Int J Mol Med; 2014 Aug 05; 34(2):513-32. PubMed ID: 24899129
    [Abstract] [Full Text] [Related]

  • 29. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY, Xu YP, Jin W, Lou LG.
    Anticancer Drugs; 2012 Aug 05; 23(7):698-705. PubMed ID: 22441567
    [Abstract] [Full Text] [Related]

  • 30. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
    Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H.
    J Clin Oncol; 2006 Feb 01; 24(4):688-94. PubMed ID: 16446342
    [Abstract] [Full Text] [Related]

  • 31. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
    Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S.
    Mol Cancer Ther; 2016 May 01; 15(5):842-53. PubMed ID: 26839308
    [Abstract] [Full Text] [Related]

  • 32. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
    Azijli K, van Roosmalen IA, Smit J, Pillai S, Fukushima M, de Jong S, Peters GJ, Bijnsdorp IV, Kruyt FA.
    Cancer Chemother Pharmacol; 2014 Jun 01; 73(6):1273-83. PubMed ID: 24744163
    [Abstract] [Full Text] [Related]

  • 33. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
    Chen YM, Perng RP, Shih JF, Whang-Peng J.
    Lung Cancer; 2008 Aug 01; 61(2):214-9. PubMed ID: 18243407
    [Abstract] [Full Text] [Related]

  • 34. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
    Zhang BY, Wang YM, Gong H, Zhao H, Lv XY, Yuan GH, Han SR.
    Int J Clin Exp Pathol; 2015 Aug 01; 8(1):25-37. PubMed ID: 25755690
    [Abstract] [Full Text] [Related]

  • 35. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.
    Lung Cancer; 2010 Aug 01; 69(2):155-64. PubMed ID: 19962780
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
    Jarząb A, Łuszczki JJ, Guz M, Gumbarewicz E, Polberg K, Stepulak A.
    Anticancer Res; 2017 Mar 01; 37(3):1067-1074. PubMed ID: 28314266
    [Abstract] [Full Text] [Related]

  • 38. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
    Shah RD, Jagtap JC, Mruthyunjaya S, Shelke GV, Pujari R, Das G, Shastry P.
    J Cell Biochem; 2013 Apr 01; 114(4):854-63. PubMed ID: 23097134
    [Abstract] [Full Text] [Related]

  • 39. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Besson F.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [Abstract] [Full Text] [Related]

  • 40. Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway.
    Ji X, Wang Z, Sarkar FH, Gupta SV.
    Anticancer Res; 2012 Jul 01; 32(7):2647-55. PubMed ID: 22753722
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.